Anavex Life Sciences Corp (AVXL)

[sokol]

I am having difficulty conceiving how the placebo effect may apply to an AD clinical trial as Adam F claimed this morning. For example, how could it account for improvements in the EEG/ERP (P300) signal? The P300 (P3) as I understand is a wave event component elicited in the process of decision making. P300 may be recorded by electroencephalography (EEG) -- measured by electrodes. It is an objective measure of brain waves.

Also, Alzheimer's robs AD patients of short term memory. How can the placebo effect make a difference in short term memory when AD patients have difficulty in remembering recent prescriptions, what they should be taking, and why?